mirabegron + rifampin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics of YM178
Conditions
Pharmacokinetics of YM178
Trial Timeline
Oct 1, 2008 → Dec 1, 2008
NCT ID
NCT00776516About mirabegron + rifampin
mirabegron + rifampin is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics of YM178. The current trial status is completed. This product is registered under clinical trial identifier NCT00776516. Target conditions include Pharmacokinetics of YM178.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetics of YM178 were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00776516 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics of YM178